iSpecimen Inc (ISPC)vsNatera Inc (NTRA)
ISPC
iSpecimen Inc
$3.00
-2.28%
HEALTHCARE · Cap: $4.34M
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 243299% more annual revenue ($2.50B vs $1.03M). ISPC leads profitability with a 0.0% profit margin vs -9.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).
ISPC
Avoid15
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.8%
Fair Value
$0.79
Current Price
$3.00
$2.21 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ISPC
The strongest argument for ISPC centers on Price/Book.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : ISPC
The primary concerns for ISPC are EPS Growth, Market Cap, Profit Margin.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ISPC profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
ISPC carries more volatility with a beta of 1.62 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
NTRA scores higher overall (31/100 vs 15/100) and 38.8% revenue growth. ISPC offers better value entry with a 60.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
iSpecimen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
iSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?